382 related articles for article (PubMed ID: 37304295)
1. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
[TBL] [Abstract][Full Text] [Related]
2. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
3. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
4. Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties.
Fujiwara K; Masutani M; Tachibana M; Okada N
Biochem Biophys Res Commun; 2020 Jun; 527(2):350-357. PubMed ID: 32216966
[TBL] [Abstract][Full Text] [Related]
5. Fully human antibody V
Wang G; Zhou X; Fucà G; Dukhovlinova E; Shou P; Li H; Johnston C; Mcguinness B; Dotti G; Du H
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795386
[TBL] [Abstract][Full Text] [Related]
6. Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H; Meeus F; De Vlaeminck Y; Lecocq Q; Puttemans J; Debie P; De Groof TWM; Goyvaerts C; De Veirman K; Breckpot K; Devoogdt N
Front Immunol; 2024; 15():1389018. PubMed ID: 38720898
[TBL] [Abstract][Full Text] [Related]
7. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
8. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30
Hombach AA; Rappl G; Abken H
Mol Ther; 2019 Oct; 27(10):1825-1835. PubMed ID: 31331813
[TBL] [Abstract][Full Text] [Related]
9. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine.
Cha SE; Kujawski M; J Yazaki P; Brown C; Shively JE
Oncoimmunology; 2021 Mar; 10(1):1899469. PubMed ID: 33796409
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
[TBL] [Abstract][Full Text] [Related]
12. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Shabaneh TB; Stevens AR; Stull SM; Shimp KR; Seaton BW; Gad EA; Jaeger-Ruckstuhl CA; Simon S; Koehne AL; Price JP; Olson JM; Hoffstrom BG; Jellyman D; Riddell SR
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38325903
[TBL] [Abstract][Full Text] [Related]
13. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
14. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
15. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
16. Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector.
Smith EL; Staehr M; Masakayan R; Tatake IJ; Purdon TJ; Wang X; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Riviere I; Liu C; Brentjens RJ
Mol Ther; 2018 Jun; 26(6):1447-1456. PubMed ID: 29678657
[TBL] [Abstract][Full Text] [Related]
17. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.
Giardino Torchia ML; Gilbreth R; Merlino A; Sult E; Monks N; Chesebrough J; Tammali R; Chu N; Tong J; Meekin J; Schifferli K; Vashisht K; DaCosta K; Clarke L; Gesse C; Yao XT; Bridges C; Moody G
Cytotherapy; 2022 Jul; 24(7):720-732. PubMed ID: 35570170
[TBL] [Abstract][Full Text] [Related]
18. A single-chain antibody generation system yielding CAR-T cells with superior antitumor function.
Ochi T; Maruta M; Tanimoto K; Kondo F; Yamamoto T; Kurata M; Fujiwara H; Masumoto J; Takenaka K; Yasukawa M
Commun Biol; 2021 Mar; 4(1):273. PubMed ID: 33654176
[TBL] [Abstract][Full Text] [Related]
19. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
20. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
